Last reviewed · How we verify
Placebo matching Ribavirin
This is a placebo control matching the appearance and dosing schedule of ribavirin, an antiviral nucleoside analog that inhibits viral RNA synthesis.
This is a placebo control matching the appearance and dosing schedule of ribavirin, an antiviral nucleoside analog that inhibits viral RNA synthesis. Used for Placebo control in phase 3 clinical trials for viral infections (specific indication dependent on trial design).
At a glance
| Generic name | Placebo matching Ribavirin |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Nucleoside analog antiviral (placebo formulation) |
| Target | Inosine monophosphate dehydrogenase (IMPDH) / viral RNA polymerase (ribavirin mechanism) |
| Modality | Small molecule |
| Therapeutic area | Virology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ribavirin is a guanosine analog that interferes with viral replication by inhibiting inosine monophosphate dehydrogenase and depleting guanosine nucleotides, thereby reducing viral RNA synthesis. As a placebo matching formulation, this product is used in clinical trials to maintain blinding while controlling for the effects of ribavirin itself. The placebo is designed to be indistinguishable from active ribavirin in appearance and administration.
Approved indications
- Placebo control in phase 3 clinical trials for viral infections (specific indication dependent on trial design)
Common side effects
- No adverse events expected (placebo)
Key clinical trials
- The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160) (PHASE3)
- A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038) (PHASE2)
- Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection (PHASE2)
- Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007) (PHASE2)
- Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009) (PHASE2)
- Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects (PHASE2)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE2)
- Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching Ribavirin CI brief — competitive landscape report
- Placebo matching Ribavirin updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI